regulation is the sole category represented across all 1 tracked stories. Disc Medicine is most often covered alongside APOLLO, which appears in 1 of these 1 story. Disc Medicine appears in 1 tracked Healthcare story from February 23, 2026. The tracked stories average 2 original sources each.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Disc Medicine
regulation is the sole category represented across all 1 tracked stories. Disc Medicine is most often covered alongside APOLLO, which appears in 1 of these 1 story. Disc Medicine appears in 1 tracked Healthcare story from February 23, 2026. The tracked stories average 2 original sources each.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 10 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Disc Medicine. Shared-story counts are live from our verified record — not editorial picks.
Disc Medicine is shifting its regulatory strategy for bitopertin in erythropoietic protoporphyria (EPP) after receiving a Complete Response Letter from the FDA. The company will now pursue a traditional approval pathway, with critical Phase 2 APOLLO trial data expected in the fourth quarter of 2026.